Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics

From: Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Baseline demographics/patient characteristics Placebo, n = 83 Paliperidone palmitate
   234/39 mg, n = 72 234/156 mg, n = 72 234/234 mg, n = 85
Age in years, mean (SD) 40.3 (11.2) 40.1 (10.2) 38.4 (10.6) 39.0 (11.0)
Sex, n (%)
   Male 56 (67.5) 50 (69.4) 47 (65.3) 60 (70.6)
   Female 27 (32.5) 22 (30.6) 25 (34.7) 25 (29.4)
Race, n (%)
   Caucasian 39 (47.0) 40 (55.6) 35 (48.6) 40 (47.1)
   African American 36 (43.4) 24 (33.3) 26 (36.1) 35 (41.2)
   Asian 8 (9.6) 5 (6.9) 10 (13.9) 6 (7.1)
   Other 0 (0) 3 (4.2) 1 (1.4) 4 (4.7)
Age at diagnosis in years, mean (SD) 24.9 (8.1) 24.2 (6.8) 25.8 (8.7) 24.3 (8.0)
Baseline PANSS total score, mean (SD) 92.6 (9.2) 95.8 (8.9) 94.5 (7.9) 96.0 (9.2)
Baseline CGI-S score, n (%)
   Marked (= 5) 73 (88.0) 60 (83.3) 68 (94.4) 74 (87.1)
   Severe (≥6) 10 (12.1) 12 (16.7) 4 (5.6) 11 (12.9)
Prior hospitalization for psychosis, n (%)
   None 5 (6.0) 5 (6.9) 6 (8.3) 7 (8.2)
   1 19 (22.9) 10 (13.9) 9 (12.5) 11 (12.9)
   2 16 (19.3) 13 (18.1) 18 (25.0) 17 (20.0)
   3 9 (10.8) 12 (16.7) 13 (18.1) 12 (14.1)
   ≥4 34 (41.0) 32 (44.4) 26 (36.1) 38 (44.7)
Disposition
   Completed, n (%) 32 (38.6) 35 (48.6) 36 (50.0) 43 (50.6)
   Discontinued, n (%) 51 (61.5) 37 (51.4) 36 (50.0) 42 (49.4)
Reasons for discontinuation
Lack of efficacy 24 (28.9) 16 (22.2) 14 (19.4) 14 (16.5)
Withdrew consent 14 (16.9) 10 (13.9) 11 (15.3) 21 (24.7)
Adverse event 7 (8.4) 6 (8.3) 7 (9.7) 5 (5.9)
Lost to follow-up 4 (4.8) 5 (6.9) 3 (4.2) 1 (1.2)
Other 2 (2.4) 0 (0) 1 (1.4) 1 (1.2)
  1. Each paliperidone palmitate subject received 234 mg of paliperidone palmitate on day 1 and then their assigned dose day 8 and monthly thereafter.
  2. CGI-S = Clinical Global Impression-Severity scale; PANSS = Positive and Negative Syndrome Scale.